arXiv subjects

Mike Tyers

Publications and source records attributed to Mike Tyers.

6 recordsLinked to original sources

arXiv2025

Discontinuous Epitope Fragments as Sufficient Target Templates for Efficient Binder Design

Recent advances in structure-based protein design have accelerated de novo binder generation, yet interfaces on large domains or spanning multiple domains remain challenging due to high computational cost and declining success with increasing target size. We hypothesized that protein folding neural networks (PFNNs) operate in a ``local-first'' manner, prioritizing local interactions while displaying limited sensitivity to global foldability. Guided by this hypothesis, we propose an epitope-only strategy that retains only the discontinuous surface residues surrounding the binding site. Compared to intact-domain workflows, this approach improves in silico success rates by up to 80% and reduces the average time per successful design by up to forty-fold, enabling binder design against previously intractable targets such as ClpP and ALS3. Building on this foundation, we further developed a tailored pipeline that incorporates a Monte Carlo-based evolution step to overcome local minima and a position-specific biased inverse folding step to refine sequence patterns. Together, these advances not only establish a generalizable framework for efficient binder design against structurally large and otherwise inaccessible targets, but also support the broader ``local-first'' hypothesis as a guiding principle for PFNN-based design.

q-bio.BM↗

arXiv2025

SynCoGen: Synthesizable 3D Molecule Generation via Joint Reaction and Coordinate Modeling

Synthesizability remains a critical bottleneck in generative molecular design. While recent advances have addressed synthesizability in 2D graphs, extending these constraints to 3D for geometry-based conditional generation remains largely unexplored. In this work, we present SynCoGen (Synthesizable Co-Generation), a single framework that combines simultaneous masked graph diffusion and flow matching for synthesizable 3D molecule generation. SynCoGen samples from the joint distribution of molecular building blocks, chemical reactions, and atomic coordinates. To train the model, we curated SynSpace, a dataset family containing over 1.2M synthesis-aware building block graphs and 7.5M conformers. SynCoGen achieves state-of-the-art performance in unconditional small molecule graph and conformer co-generation. For protein ligand generation in drug discovery, the amortized model delivers superior performance in both molecular linker design and pharmacophore-conditioned generation across diverse targets without relying on any scoring functions. Overall, this multimodal non-autoregressive formulation represents a foundation for a range of molecular design applications, including analog expansion, lead optimization, and direct de novo design.

cs.LG↗

arXiv2025

Scalable and Cost-Efficient de Novo Template-Based Molecular Generation

Template-based molecular generation offers a promising avenue for drug design by ensuring generated compounds are synthetically accessible through predefined reaction templates and building blocks. In this work, we tackle three core challenges in template-based GFlowNets: (1) minimizing synthesis cost, (2) scaling to large building block libraries, and (3) effectively utilizing small fragment sets. We propose Recursive Cost Guidance, a backward policy framework that employs auxiliary machine learning models to approximate synthesis cost and viability. This guidance steers generation toward low-cost synthesis pathways, significantly enhancing cost-efficiency, molecular diversity, and quality, especially when paired with an Exploitation Penalty that balances the trade-off between exploration and exploitation. To enhance performance in smaller building block libraries, we develop a Dynamic Library mechanism that reuses intermediate high-reward states to construct full synthesis trees. Our approach establishes state-of-the-art results in template-based molecular generation.

q-bio.BM↗

arXiv2024

RGFN: Synthesizable Molecular Generation Using GFlowNets

Generative models hold great promise for small molecule discovery, significantly increasing the size of search space compared to traditional in silico screening libraries. However, most existing machine learning methods for small molecule generation suffer from poor synthesizability of candidate compounds, making experimental validation difficult. In this paper we propose Reaction-GFlowNet (RGFN), an extension of the GFlowNet framework that operates directly in the space of chemical reactions, thereby allowing out-of-the-box synthesizability while maintaining comparable quality of generated candidates. We demonstrate that with the proposed set of reactions and building blocks, it is possible to obtain a search space of molecules orders of magnitude larger than existing screening libraries coupled with low cost of synthesis. We also show that the approach scales to very large fragment libraries, further increasing the number of potential molecules. We demonstrate the effectiveness of the proposed approach across a range of oracle models, including pretrained proxy models and GPU-accelerated docking.

physics.chem-ph↗

arXiv2024

Generative Active Learning for the Search of Small-molecule Protein Binders

Despite substantial progress in machine learning for scientific discovery in recent years, truly de novo design of small molecules which exhibit a property of interest remains a significant challenge. We introduce LambdaZero, a generative active learning approach to search for synthesizable molecules. Powered by deep reinforcement learning, LambdaZero learns to search over the vast space of molecules to discover candidates with a desired property. We apply LambdaZero with molecular docking to design novel small molecules that inhibit the enzyme soluble Epoxide Hydrolase 2 (sEH), while enforcing constraints on synthesizability and drug-likeliness. LambdaZero provides an exponential speedup in terms of the number of calls to the expensive molecular docking oracle, and LambdaZero de novo designed molecules reach docking scores that would otherwise require the virtual screening of a hundred billion molecules. Importantly, LambdaZero discovers novel scaffolds of synthesizable, drug-like inhibitors for sEH. In in vitro experimental validation, a series of ligands from a generated quinazoline-based scaffold were synthesized, and the lead inhibitor N-(4,6-di(pyrrolidin-1-yl)quinazolin-2-yl)-N-methylbenzamide (UM0152893) displayed sub-micromolar enzyme inhibition of sEH.

q-bio.BM↗

arXiv2022

RECOVER: sequential model optimization platform for combination drug repurposing identifies novel synergistic compounds in vitro

For large libraries of small molecules, exhaustive combinatorial chemical screens become infeasible to perform when considering a range of disease models, assay conditions, and dose ranges. Deep learning models have achieved state of the art results in silico for the prediction of synergy scores. However, databases of drug combinations are biased towards synergistic agents and these results do not necessarily generalise out of distribution. We employ a sequential model optimization search utilising a deep learning model to quickly discover synergistic drug combinations active against a cancer cell line, requiring substantially less screening than an exhaustive evaluation. Our small scale wet lab experiments only account for evaluation of ~5% of the total search space. After only 3 rounds of ML-guided in vitro experimentation (including a calibration round), we find that the set of drug pairs queried is enriched for highly synergistic combinations; two additional rounds of ML-guided experiments were performed to ensure reproducibility of trends. Remarkably, we rediscover drug combinations later confirmed to be under study within clinical trials. Moreover, we find that drug embeddings generated using only structural information begin to reflect mechanisms of action. Prior in silico benchmarking suggests we can enrich search queries by a factor of ~5-10x for highly synergistic drug combinations by using sequential rounds of evaluation when compared to random selection, or by a factor of >3x when using a pretrained model selecting all drug combinations at a single time point.

q-bio.QM↗